Immupharma PLC Result of AGM (4340Z)
May 26 2016 - 8:00AM
UK Regulatory
TIDMIMM
RNS Number : 4340Z
Immupharma PLC
26 May 2016
FOR IMMEDIATE RELEASE 26 MAY 2016
2016 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED
LUPUZOR(TM) SYMPOSIUM: 8 & 9 JUNE 2016
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, held its AGM
earlier today and is pleased to announce that all resolutions were
duly passed. A summary of proxy votes is shown in the table below.
Please also refer to the 'Notice of the 2016 Annual General
Meeting' in the Report & Accounts - 31 December 2015 (page
60).
RESOLUTION FOR + % AGAINST % WITHHELD
DISCRETION
------------ ------------ ------ -------- ----- ---------
1 42,327,430 99.90 40,400 0.10 25,000
------------ ------------ ------ -------- ----- ---------
2 42,307,657 99.86 60,173 0.14 25,000
------------ ------------ ------ -------- ----- ---------
3 42,352,430 99.90 40,400 0.10 0
------------ ------------ ------ -------- ----- ---------
4 42,352,430 99.90 40,400 0.10 0
------------ ------------ ------ -------- ----- ---------
5 42,344,328 99.89 48,502 0.11 0
------------ ------------ ------ -------- ----- ---------
Special
Resolution
6 42,327,503 99.87 53,502 0.13 11,825
------------ ------------ ------ -------- ----- ---------
Lupuzor Symposium : Key Presenter : Prof. Sylviane Muller
As announced at the recent Preliminary Results, a Lupuzor(TM)
Symposium is being hosted where Prof. Muller, inventor of
Lupuzor(TM) will present on the unique 'Mechanism of Action' of
Lupuzor(TM), also known by its chemical name 'Forigerimod' or
'P140'. Prof. Muller will also provide further evidence of the role
the P140 molecule can take in the potential treatment of other
autoimmune diseases.
Investor meetings as part of this Symposium are being held on
both days. A sell-side analyst and media briefing will be held on 9
June @ 11:00 am at 50 Basinghall Street, EC2. For more information
or if you would like to attend one of the briefings, please email:
lisa.baderoon@immupharma.com.
For further information please see the Company's web site,
www.immupharma.org, or contact:
-Ends-
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413 496
Panmure, Gordon & Co., NOMAD & +44 (0) 20 7886
Broker 2500
Fred Walsh, Duncan Monteith, Corporate
Finance
Charles Leigh-Pemberton, Corporate
Broking
Notes to Editors
ImmuPharma PLC
ImmuPharma is a pharmaceutical development company listed since
2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on
developing novel medicines with high sales potential in specialist
markets with serious unmet need. ImmuPharma is led by a
commercially focused Board and management team with extensive
experience.
ImmuPharma announced on 1 March 2016 the successful completion
of a GBP8.4 million fund raise, comprising a Placing and
Subscription together with confirmation of EIS and VCT qualifying
status. Monies raised will principally be used to complete the
pivotal Phase III trial of Lupuzor(TM). Following the issue of the
New Ordinary Shares ImmuPharma has 121,781,219 ordinary shares of
10 pence each (the "Ordinary Shares") in issue.
Lupuzor(TM)
Lupuzor(TM) (also referred to as Forigerimod, or P140) is
ImmuPharma's lead compound and a potential treatment for lupus (or
Systemic Lupus Erythematosus), a chronic, potentially
life-threatening auto-immune disease. Lupuzor(TM) has a novel
mechanism of action aimed at modulating the body's immune system so
that it does not attack healthy cells, and avoids causing adverse
side effects. It has the potential to halt the progression of the
disease in a substantial proportion of patients.
Lupuzor(TM) has been granted Fast Track status by the US FDA and
approval to start Phase III under Special Protocol Assessment
(SPA). This SPA was subsequently amended due to its strong safety
and efficacy profile to allow for a reduced number of patients in
the pivotal Phase III trial thereby reducing the projected cost and
time of development considerably.
The pivotal Phase III clinical study is entitled "A 52-Week,
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study
to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101
Plus Standard of Care in Patients With Systemic Lupus
Erythematosus". It is a pivotal study designed to demonstrate the
safety and efficacy of IPP-201101 and as a last step prior to the
filing of the drug for approval with the US Food & Drug
Administration ("FDA") and the European Medicines Agency ("EMA").
For more information please visit:
www.ClinicalTrials.gov/lupuzor
Commercial Opportunity
There are an estimated five million people globally suffering
from Lupus, with approximately 1.5 million patients in the US,
Europe and Japan (Source: Lupus Foundation of America). Current
'standard of care' treatments, including steroids and
immunosuppressants, can potentially have either serious side
effects for patients or limited effectiveness, with over 60% of
patients not adequately treated. GSK's Benlysta is the first Lupus
drug approved in over 50 years and paves the path to market for
Lupuzor(TM). Based on conservative estimates, and taking into
account that Benlysta is priced currently at approximately $35,000
per patient per year, Lupuzor(TM) would be entering a market with
the potential for multi-billion dollar sales. For more information
on Lupuzor(TM) please visit: www.lupuzor.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGKMGZKZVRGVZM
(END) Dow Jones Newswires
May 26, 2016 09:00 ET (13:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024